Skip to main content Skip to footer Opens in a new tab

About
Services
Clinical Trials
Resources
Contact Us

About
Services
Clinical Trials
Resources
Contact Us

A Phase 1 Dose Escalation Study of the Tolerability, Safety, Efficacy and Pharmacokinetics of ZG006 in Small Cell Lung Cancer

Logan Coy·September 11, 2026·0 comments

Logan Coy

Related posts

Randomized, open-label study of the BRIA-IMT regimen and checkpoint inhibitor vs physician’s choice in advanced metastatic breast cancer (BRIA-ABC)
September 10, 2026
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer After Prior Chemotherapy
September 11, 2026
A Phase 1b/2, Single-Arm, Open-Label, Dose-Escalation Study of Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory Small Cell Lung Cancer
September 11, 2026

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician’s Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCLC (VIRO-25)

A Phase 2/3, multisite, randomized master protocol for a global trial of BNT327 in combination with chemotherapy and other investigational agents in first-line non-small cell lung cancer

4875 Higbee Ave NW
Canton, OH 44718
(330) 492-3345 or (330) 844-5500
srentsch@gabrailcancercenter.com

About Services Clinical Trials Resources Contact Us

Website Privacy Policy

Notice of Privacy Practices (HIPAA)

Clinical Research Privacy Notice